Omega Diagnostics: H1 Sales Up By 8%
Edison | Dec 08, 2015 04:41AM ET
Allersys launch targeted for spring 2016
Omega Diagnostics Group Plc (L:ODX): H1 results (30 November 2015) noted that the Allersys allergy system could launch in spring 2016, with 37 optimised assays out of 40 targeted for launch. Omega’s Visitect CD4 test to monitor HIV patients shows a variability related to the ambient temperature. The cause is now known and a solution is being developed; the launch date is still uncertain. An Indian production facility in Pune starts operation in FY17 and should lead to sales gains in infectious disease products. Overall H1 sales were up 8% at £6.2m. Adjusted EPS was higher at 0.6p vs 0.5p due to a £135k tax credit.
Allersys: On track for spring 2016
The Allersys range runs on the Immunodiagnostic Systems (IDS) iSYS system using modern chemistry and magnetic particles. An initial customer evaluation in Spain on 10 allergens with 400 samples showed a linear relationship with ImmunoCap. Italian, German and French studies are planned, some with IDS. There are now 37 optimised allergens with 26 fully verified; 40 are being targeted for launch. IDS’s partners have developed autoimmune tests that run on iSYS and complement allergy tests. Management indicates a spring 2016 launch.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.